Becton Dickinson (NYSE:BDX) said today that it launched its BD Neopak 2.25 milliliter prefillable glass syringe designed for high-volume injection of biologics.
The Franklin Lakes, N.J.-based company said that its prefillable glass syringe was developed to reduce drug degradation and aggregation between the container and therapeutic. The high volume syringe is commercially available in the U.S., Europe and Japan.
Some sensitive biologic drugs require a higher volume to treat chronic diseases, such as lupus and rheumatoid arthritis.
“Through our continued investment in innovation, this new syringe enables biopharmaceutical manufacturers to develop drug-syringe combination products with extended injection intervals. This will provide patients with more time between injections and decrease the frequency of injections,” BD global president of pharmaceutical systems Peter Nolan said in prepared remarks. “By offering higher volume subcutaneous injections, the BD Neopak 2.25 mL prefillable glass syringe is designed to help reduce the number of necessary injections, aiming to improve the safety and convenience for patients.”
This month BD said that it adopted the Windows 10 Internet of Things operating system for its automated drug-dispensing Pyxis ES system. The new operating system features long-term support and improved cybersecurity, with new features and upgrades for the system every 2 to 3 years.
